05:11 PM EDT, 09/12/2024 (MT Newswires) -- Immuneering ( IMRX ) shares surged 52% in after-hours activity Thursday after the company said complete or partial response was observed in the first two patients with first-line pancreatic cancer getting IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in a phase 2a study.

The initial response rate in the trial was 40% while the initial disease control rate was 80%, the company said Thursday in a statement.

All five patients in the study are continuing treatment after "positive initial response data," Immuneering ( IMRX ) said.

Additional patients were dosed with 320 milligrams once daily, and the drug is well tolerated in combination with gemcitabine/nab-paclitaxel, the company said.

Price: 2.17, Change: +0.74, Percent Change: +51.75